Financial Performance - The company's revenue for Q1 2022 was ¥366,344,805.12, representing a decrease of 38.46% compared to the same period last year[5] - Net profit attributable to shareholders was ¥150,924,190.74, down 46.16% year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥132,845,531.04, reflecting a decline of 53.21% compared to the previous year[5] - Basic earnings per share decreased by 52.00% to ¥0.36[5] - Total operating revenue for Q1 2022 was ¥366,344,805.12, a decrease of 38.5% compared to ¥595,277,477.18 in Q1 2021[38] - Net profit for Q1 2022 was ¥150,924,190.74, a decline of 46.3% from ¥280,299,418.02 in Q1 2021[40] - Basic and diluted earnings per share for Q1 2022 were both ¥0.36, compared to ¥0.75 in Q1 2021[41] - The net profit for Q1 2022 was ¥178,776,652.90, down 37.4% from ¥285,751,337.31 in Q1 2021[56] Research and Development - R&D investment totaled ¥69,235,416.34, a decrease of 16.42%, but accounted for 18.90% of revenue, an increase of 4.98 percentage points[7] - The company has initiated the construction of a biotechnology product R&D and production base with an estimated investment of RMB 1.4 billion to support the production needs of its HPV vaccine and other products[25] - The company is actively developing its ACYW135 meningococcal polysaccharide conjugate vaccine, with clinical trial applications accepted in March 2022[23] - Research and development expenses for Q1 2022 were ¥47,298,376.40, down 26.4% from ¥64,259,108.26 in Q1 2021[38] - Research and development expenses for Q1 2022 were ¥29,011,936.92, down 51.5% from ¥59,789,820.21 in Q1 2021[56] Cash Flow and Liquidity - The net cash flow from operating activities was ¥38,146,275.72, with an increase in cash received from sales compared to the previous year[13] - In Q1 2022, the company reported a net cash flow from operating activities of ¥38,146,275.72, a significant improvement compared to a net outflow of ¥27,054,458.17 in Q1 2021[43] - The company's cash inflow from operating activities totaled ¥320,536,823.33 in Q1 2022, an increase of 22.2% from ¥262,351,166.86 in Q1 2021[60] - Cash and cash equivalents at the end of Q1 2022 amounted to ¥2,270,823,998.45, down from ¥365,354,543.10 at the end of Q1 2021[45] - The net cash flow from investment activities was negative at ¥540,349,528.56, slightly better than the negative ¥593,850,177.17 recorded in Q1 2021[45] - Cash flow from financing activities resulted in a net outflow of -365,495.58, compared to -354,850.08 in the previous period[63] - The net increase in cash and cash equivalents for the period was -510,753,753.85, showing a decrease in liquidity[63] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,889,979,317.86, a slight increase of 0.99% from the end of the previous year[7] - The company's total assets increased to RMB 9,889,979,317.86 as of March 31, 2022, compared to RMB 9,792,731,456.06 as of December 31, 2021, reflecting a growth of about 1.0%[30] - The company's inventory as of March 31, 2022, was RMB 413,638,378.11, up from RMB 385,155,199.04 as of December 31, 2021, indicating an increase of approximately 7.0%[30] - Total liabilities decreased to ¥387,039,579.03 in the latest report from ¥440,715,907.97 in the previous period[33] - The company's total liabilities decreased to ¥249,198,833.13 in Q1 2022 from ¥421,212,228.65 in Q1 2021, representing a reduction of 40.8%[56] - The company's total equity increased to ¥9,602,030,411.99 in Q1 2022 from ¥9,423,253,759.09 in Q1 2021, reflecting a growth of 1.9%[56] Market Conditions - The decline in revenue was attributed to the impact of the Omicron variant and tightened domestic pandemic control measures, leading to reduced market demand[12] - The company faced increased competition in the human rabies vaccine market, contributing to the revenue decline[12] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,021[15] - Four of the top ten shareholders are involved in margin trading, holding a total of 73.43 million shares through credit securities accounts[20]

Financial Performance - The company achieved a net profit attributable to shareholders of the parent company of ¥892,490,658.44 in 2021, with a total profit available for distribution to shareholders of ¥892,229,814.14 after statutory surplus reserve allocation[8]. - A cash dividend of ¥10 per 10 shares (including tax) is proposed, totaling ¥416,450,000, which accounts for 46.66% of the net profit attributable to shareholders of the parent company for 2021[8]. - The company reported a total revenue of RMB 1.2 billion for the fiscal year 2021, representing a year-over-year growth of 15%[26]. - The company achieved operating revenue of CNY 2,088,043,469.78 in 2021, representing a year-on-year increase of 4.63%[33]. - The net profit attributable to shareholders was CNY 892,490,658.44, a decrease of 2.80% compared to the previous year[37]. - The net profit after deducting non-recurring gains and losses was CNY 862,518,502.00, reflecting a year-on-year increase of 2.13%[37]. - The net cash flow from operating activities was CNY 506,376,172.18, down 41.09% year-on-year, primarily due to delayed customer payments caused by the COVID-19 pandemic[37]. - The company's total assets reached CNY 9,792,731,456.06 at the end of 2021, an increase of 118.67% compared to the end of 2020[38]. - The net assets attributable to shareholders increased to CNY 9,352,015,548.09, marking a growth of 127.09% year-on-year[38]. - Basic earnings per share decreased by 4.49% to CNY 2.34 in 2021[36]. Research and Development - The R&D expenditure accounted for 14.91% of operating revenue, an increase of 3.77 percentage points compared to the previous year[36]. - The company has established three major R&D technology platforms, with over 20 vaccine varieties currently under research, including innovative and multi-valent vaccines[66]. - The company’s total R&D investment for the year reached ¥311,399,620.91, representing a year-on-year increase of 40.04% and accounting for 14.91% of the company's operating revenue[112][113]. - The company filed 17 new intellectual property applications during the reporting period, including 9 invention patent applications, and received 3 patent grants[111]. - The number of R&D personnel increased to 170, up from 155 in the previous year, with R&D personnel accounting for 11.12% of the total workforce[121]. - The company is currently conducting clinical trials for several vaccines, including the quadrivalent influenza vaccine, which is in Phase III trials with a total investment of ¥29,800,000[117]. - The company is actively expanding its R&D efforts, with a focus on new product development and clinical trials for various vaccines[113][117]. - The company has established three distinct technology platforms for vaccine development: bacterial vaccines, viral vaccines, and multi-valent vaccines, aligning with industry trends[102]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share by 2025[26]. - The company has completed the acquisition of a local biotech firm, which is expected to enhance its R&D capabilities and product pipeline[26]. - The company is enhancing its management system post-listing, focusing on risk prevention and talent recruitment to support future development[62]. - The company is committed to increasing R&D investment to mitigate long-term technology iteration risks and ensure the leading position of its core technology[129]. - The company is focusing on expanding its product portfolio to reduce risks associated with a relatively single product structure, particularly in rabies and encephalitis vaccines[135]. Operational Challenges and Risks - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[12]. - The company has not violated decision-making procedures for external guarantees[12]. - The company has not faced any issues with more than half of the directors being unable to ensure the authenticity, accuracy, and completeness of the annual report[12]. - The company is closely monitoring macroeconomic conditions to manage investment risks effectively[145]. - The company faces potential foreign exchange risks due to international sales and purchases, which could impact financial performance[148]. - The company is increasing R&D investments to address the risk of declining demand for human rabies vaccines in the long term[149]. Product Development and Innovation - The company is currently developing a new mRNA vaccine, expected to enter clinical trials by Q3 2022[26]. - The approval for clinical trials of the 15-valent HPV vaccine was received in December 2021, marking a significant breakthrough in innovative vaccine projects[53]. - The company is advancing the development of new technologies and processes for its existing vaccines, including the human rabies vaccine and the human Japanese encephalitis vaccine[66]. - The company’s innovative approaches in vaccine technology, such as the use of VLP technology, are expected to improve the safety and efficacy of its vaccine products[106]. Sales and Marketing - User data indicates that the company has expanded its customer base by 20% in the last year, reaching a total of 5 million active users[26]. - The company has a strong domestic sales team of nearly 300 professionals, covering all provinces and regions in China, and an international sales network in over 30 countries[128]. - The company is enhancing its marketing network and expanding its sales team to improve market penetration and brand recognition[139]. - The company has established strict management protocols for third-party promotional agencies and overseas distributors to mitigate risks[140]. Audit and Compliance - The company has received a standard unqualified audit opinion from Rongcheng Accounting Firm[7]. - The company has not reported any special arrangements for corporate governance[9].